Dr Rebecca K Sutherland
Dr Rebecca Sutherland is a Consultant in Infectious Diseases at the Western General Hospital, Edinburgh.
Background
Dr Rebecca Sutherland was appointed as Consultant in Infectious Diseases in 2012 at the Western General Hospital, NHS Lothian. Prior to moving back to Edinburgh, Dr Sutherland trained in Infectious Diseases and Microbiology in Oxford and was a research fellow in vaccine immunology in the Weatherall Institute of Molecular Medicine.
Research Interest
- Optimizing antimicrobial therapy for clinical infection
- HIV therapeutics and standards of care
- Covid-19 vaccines
Projects/grants
- Local PI for Oral vs IV therapy for bone and joint infection (OvIVA)
- Local PI for Oxford nCovid-19 vaccine study
Selected Publications
2021
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire - PubMed (nih.gov) Phillip A Swanson, Marcelino Padilla, Wesley Hoyland, Kelly McGlinchey, Rebecca K Sutherland,....Christopher J Williams et al. (online awaiting publication).
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS_CoV-2 VOC 202012/01 (B.1.1.7) Katherine Emary, Golubchik Y, Aley P, Ariani C, …, Rebecca K Sutherland, …, Alexander D Douglas*, Adrian V S Hill*, Teresa Lambe*, Sarah C Gilbert*, Andrew J Pollard*, on behalf of the Oxford COVID Vaccine Trial Group† Lancet Mar 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Merryn Voysey*, Sue Ann Costa Clemens*, Shabir A Madhi*, Lily Y Weckx*, Pedro M Folegatti*, …, Rebecca K Sutherland, …, Alexander D Douglas*, Adrian V S Hill*, Teresa Lambe*, Sarah C Gilbert*, Andrew J Pollard*, on behalf of the Oxford COVID Vaccine Trial Group† Lancet Feb 2021
2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of randomised controlled trials in Brazil, South Africa and the United Kingdom Merryn Voysey; Sue Ann Costa Clemens; Shabir A Madhi; Lily Yin Weckx;…; Rebecca K Sutherland;…; Andrew J Pollard, Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1.
Expect the unexpected- Implications for next phase of COVID-19 response Clifford S, Cevik C, Campbell R, O’Shea D, Sutherland R. Infect Prev Pract. 2021 Jun;3(2):100118. doi: 10.1016/j.infpip.2021.100118.
British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of gastrointestinal opportunistic infections 2020.Chadwick DR, Sutherland RK, Raffe S et al. HIV Med. 2020; 21 Suppl 5; 1-19
An Algorithm for safe de-labelling of antibiotic allergy in adult hospital inpatients Sneddon, Jacqueline; Cooper, Lesley; Ritchie, Neil; Steele, Cathal; Spears, Mark, McEwen Jo; Dempsey,Zoey; Sutherland, Rebecca; Khatamzas, Elham; Seaton,R. Clinical and Experimental Allergy. Mar 2021. 2021 Sep;51(9):1229-1232. doi: 10.1111/cea.13878.
The index case of SARS-CoV-2 in Scotland. Hill KJ, Russell CD, Clifford S, Templeton K, Mackintosh CL, Koch O, Sutherland RK. J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.022.
A retrospective review and multi-specialty, evidence-based guideline for the management of Necrotising Otitis Externa Hopkins M, Baring D, Macsween K, Henderson N, Baring D, Sutherland R . J Laryngol Otol. 2020 Jun;134(6):487-492. doi: 10.1017/S0022215120001061. Epub 2020 Jun 5.
2019
Oral versus Intravenous Antibiotics for Bone and Joint Infection. Ho-Kwong Li, Ines Rombach, Rhea Zambellas, A. Sarah Walker, …, Rebecca K. Sutherland, …and Matthew Scarborough et al for the OVIVA Trial Collaborators N Engl J Med. 2019 Jan 31;380(5):425-436. doi: 10.1056/NEJMoa1710926.
2017
Nocardia and Actinomyces. Henderson NM, Sutherland RK. Medicine Infections Chapter. Part 3 of 3. Vol 45:12 Dec 2017
2016
What you need to know about Whipple’s disease. Tsarfati EM, Sutherland R. British Journal of Hospital Medicine. 2016
2015
Diagnosis and features of hospital acquired pneumonia: a retrospective cohort study CD Russell, O Koch, IF Laurenson, DT O’Shea, R Sutherland, CL Mackintosh. Journal Hospital Infection. 2015 1-7
Elevation of the JVP in constrictive pericarditis. Sutherland R, Russell KV, Trivedi P, Richard W Smith, Conlon CP. QJM. 2015 Oct;108(10):846. doi: 10.1093/qjmed/hcv048. Epub 2015 Feb 19
2014
A constricting differential- a case of severe anaemia, weight loss and pericarditis due to Tropheryma whipplei infection. Sutherland R, Russell KV, Trivedi P, Warren B, Richard W Smith, Conlon CP. QJM. 2014 Nov;107(11):927-9. doi: 10.1093/qjmed/hcs041.
2013
Improving antimicrobial prescribing: implementation of an antimicrobial iv-to-oral switch policy. Mccallum A, Sutherland R, Mackintosh C. J R Coll Physicians. Edinb. 2013;43(4):294-300. doi: 10.4997/JRCPE.2013.403.
HIV-associated late seminal vesicle “BCGosis” following intravesical bacille Calmette-Guerin therapy. Eyre DW, Mankia K, Sutherland R, Turner G, Conlon C. 2013. J Clin Urol. 6:20–21.
2008
Lessons from IAVI-006, a phase 1 clinical trail to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Guimaraes-Walker A, Mackie N, McCormack S, Hanke T, …, Kay R,…, Fast P; IAVI-006 Study Group Vaccine. 2008 Dec 2;26(51):66671-7. doi: 10.1016/j.vaccine.2008.09.016.
2006
Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. Sutherland R, Yang H, Scriba TJ, Ondondo B, …, Dorrell L. AIDS. 2006 Apr 4;20(6):821-9. doi: 10.1097/01.aids.0000218545.31716.a4.
2005
A new dawn for antiretrovirals. Sutherland R. BMJ .2005; 330:371
2003
Vaccine for specific targets: HIV. Kay R, Wee E.G-T, McMichael AJ. Chapter in Novel Vaccine Strategies edited by Stefan HE Kaufmann, p505-528, published 2006